Recommendations focus on ways to prevent opioid misuse and reduce risk of addiction.
Marcotte
The country’s opioid crisis is estimated to have exceeded $1 trillion from 2001 to 2017, and it is predicted to cost an additional $500 billion by 2020, according to an analysis from Altarum, a nonprofit health research and consulting institute.
The impact is being felt by employers. According to the Altarum report, the costs of the opioid crisis are borne by individuals in the form of lost wages and lost productivity.
The National Business Group on Health, a nonprofit association of more than 420 large U.S. employers, is recommending employers work with their health plans and pharmacy benefits managers (PBMs) to ensure they are implementing national guidelines for prescribing opioids.
The group recommends that employers ask if their efforts and their work with clinicians includes the following:
“While health plans and PBMs have initiated various opioid management programs, opportunities remain to implement the guidelines,” says Brian Marcotte, president and CEO, of the National Business Group on Health. “The Business Group recommends employers work with their vendor partners to review the guidelines and take action to fill any gaps. In addition to the devastation it causes employees and their families, research shows opioid misuse costs employers billions of dollars from absenteeism and presenteeism alone, affects hiring and retention, and negatively impacts worker productivity, workers compensation claims, and overall medical costs. Because of the magnitude of the impact, the Business Group has prioritized educating employer members on the guidelines to urge their implementation.”
Ultimately, healthcare executives, including hospital and physician leaders, play a major role in educating clinicians, reexamining and changing prescribing guidelines and pain management protocols, and in implementing changes in clinical practice, according to Marcotte. “Healthcare executive leadership is essential to stemming this crisis and preventing further devastation,” he says.
Marcotte offers five ways for healthcare executives to help employers curb opioid abuse:
Health organizations and PBM roles
Health plans and PBMs can assist employers in assuring plan designs that are compliant with the CDC guidelines including limiting coverage for initial prescriptions to small quantities, and robust coverage of alternatives for pain management, both pharmaceutical and non-pharmaceutical, according to Marcotte.
“They can also educate members about alternatives and the risks of opioids,” he says. “When working with health plans, employers can ask them what efforts are being taken around responsible opioid prescribing, and whether the CDC guidelines are being used by physicians, hospitals, and pharmacies in their networks. Health plans should ensure that provider networks favor conservative care approach to opioid initiation and practice evidence-based treatment of opioid addiction.”
Health plans should also offer provider education on CDC guidelines and non-pharmacological alternatives for chronic pain management, and member education on the risks of opioid addiction and the availability of alternatives, he says.
“When working with PBMs, employers can ask what measures they are taking to monitor and identify overprescribing, pharmacy shopping, and other signs of inappropriate prescribing or dispensing. They can also monitor for concurrent prescribing of opioids and benzodiazepines,” he says.
According to the Business Group's Large Employers’ 2018 Health Care Strategy And Plan Design Survey, employers are working directly with their health plans and PBMs to address the issue using the following strategies:
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More